BIOHM Health Inc., a leading innovator in microbiome research, ingredients and product solutions has announced the appointment of Kristin Wilhoyte as Vice President of B2B Marketing. In this role, Wilhoyte will be instrumental in establishing and expanding the company’s business-to-business platform of microbiome technologies, including ingredients, gut health test kits and data-driven supplement formulations.
With more than 12 years of experience in the nutraceutical industry, Wilhoyte brings a wealth of knowledge and expertise to BIOHM Health. Prior to joining the company, she served as Director of Marketing at Deerland Probiotics and Enzymes, where she played a pivotal role in driving brand growth and success. Her tenure continued with ADM’s Health & Wellness division following the acquisition of Deerland in 2021.
“We are thrilled to welcome Kristin to the BIOHM team,” said Sam Schatz, CEO of BIOHM Health. “Her deep understanding of microbiome-supporting ingredients, combined with her proven experience in the nutraceutical industry, makes her a great fit to support our growth strategies. Kristin’s expertise will be instrumental in bringing BIOHM’s innovative microbiome health solutions to brands across the dietary supplement industry.”
Wilhoyte’s proven track record in the development and marketing of microbiome health products, including probiotics, prebiotics, postbiotics, and enzymes, aligns perfectly with BIOHM Health’s mission. Her leadership will be crucial as the company positions itself as a leading supplier of microbiome technologies and solutions. “BIOHM’s foundation in robust science and culture of innovation make it an exciting place to be, and I’m delighted to be part of its promising future,” Wilhoyte added.
BIOHM Health, Inc., based in Cleveland, OH, is a cutting-edge innovator in microbiome-based products and ingredients, dedicated to improving human health by prioritizing research on the critical roles of both bacteria and fungi in the microbiome. The company drives this mission through its unique gut microbiome dataset that combines bacterial and fungal sequencing with metadata, while harnessing the power of AI and deep machine learning to accelerate the discovery of novel ingredients and formulations with targeted health benefits.